1.

43例患者临床资料

Clinical characteristics of the 43 study patients

Characteristics	All (n=43), [n (%)]	PC (n=15), [n (%)]	PE (n=28), [n (%)]	P
ECOG: Eastern Cooperative Oncology Group; PR: partial response; SD: stable disease; PD: progressive disease; PC: paclitaxel/carboplatin; PE: cisplatin/etoposide.
Gender				0.215
Male	36 (83.7)	11 (73.3)	25 (89.3)
Female	7 (16.3)	4 (26.7)	3 (10.7)
Age [median (range)]	59 (41-75)	58 (41-75)	59.5 (43-70)	0.842
Smoking status				0.176
Current	28 (65.1)	7 (46.7)	21 (75.0)
Former	4 (9.3)	2 (13.3)	2 (7.1)
Never	11 (25.6)	6 (40.0)	5 (17.9)
ECOG				0.660
0	10 (23.3)	3 (20.0)	7 (25.0)
1	28 (65.1)	11 (73.3)	17 (60.7)
2	5 (11.6)	1 (6.7)	4 (14.3)
Histology				0.129
Squamous	31 (72.1)	8 (53.3)	23 (82.1)
Adenocarcinoma	10 (23.3)	6 (40.0)	4 (14.3)
Large cell	2 (4.7)	1 (6.7)	1 (3.6)
Stage				0.419
Ⅲa	8 (18.6)	4 (26.7)	4 (14.3)
Ⅲb	35 (81.4)	11 (73.3)	24 (85.7)
Response				0.638
PR	18 (41.9)	5 (33.3)	13 (46.4)
SD	21 (44.8)	8 (53.3)	13 (46.4)
PD	4 (9.3)	2 (13.3)	2 (7.1)
Progression mode				0.496
Local progression	18 (41.9)	5 (33.3)	13 (46.4)
Metastatic progression	7 (16.3)	4 (26.7)	3 (10.7)
Both	10 (23.3)	4 (26.7)	6 (21.4)
Non-progression	8 (18.6)	2 (13.3)	6 (21.4)